ReviewJournal of cardiothoracic surgery2025
Recent insights into the pathophysiology and implications for surgery in atherosclerosis.
Review in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early atherogenesis: In search of etiology.International journal of cardiology. Cardiovascular risk and prevention · 2026Review
- Atherosclerosis: A Pathologist's Perspective.Journal of cardiovascular development and disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtherosclerosis is a leading cause of cardiovascular disease. Recent advances in molecular biology have deepened our understanding of its pathogenesis and opened new avenues for surgical intervention.
methodsThis review integrates recent findings on key mechanisms-such as endoplasmic reticulum stress, oxidative imbalance, and immune-metabolic dysregulation-with progress in surgical and interventional strategies.
resultsNovel targets like UPR pathways, mitochondrial ROS, and microRNAs have shown therapeutic promise. RNA-based lipid-lowering therapies and PCSK9 inhibitors offer alternatives to statins. In parallel, innovations in PCI and CABG-such as next-generation stents, multi-arterial grafting, and engineered vascular conduits-have improved safety and efficacy. Advanced imaging techniques further enhance diagnosis and procedural planning.
conclusionIntegrating molecular insights with evolving surgical approaches is transforming atherosclerosis management. A precision strategy combining targeted therapy with individualized revascularization holds promise for better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.